The direct thrombin inhibitor edoxaban (Lixiana) has been recommended by NICE, within its marketing authorisation, as an option for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.Further information
NICE technology appraisal TA355
Patients are eligible to receive the treatment on the NHS if they have one or more risk factors, including:
- congestive heart failure
- prior stroke or transient ischaemic attack
- age 75 years or older.
In August, NICE approved edoxaban for use in treating and preventing recurrent deep vein thrombosis and pulmonary embolism in adults.